Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination

A relevant research concerning a wider perspective on protective immunity has just been published: Maura Casalgrandi, researcher in HMGBiotech, is one of the authors involved in the study.
The research shows that immunity conferred by prior infection or mRNA vaccination can protect against SARS-CoV-2 challenge regardless of antibodies. Focusing on the crucial role T cells play in providing protection against the virus is highlighted an antibody-independent mechanism of immunity conferred by prior infection or mRNA vaccination.

T cell responses can effectively protect against SARS-CoV-2 challenges without the need for antibodies. This protection hinges on the roles of CD8+ T cells in combating severe infections and CD4+ T cells in managing milder cases, with interferon-γ emerging as a key player in this defense strategy.
These significant findings suggests a paradigm shift in vaccine strategy, advocating for a comprehensive approach that encompasses not only the induction of a strong antibody response but also the stimulation of a robust T cell response.

By targeting both humoral and cellular immunity, vaccines could potentially offer broader and more durable protection against a wider array of viral variants, possibly outpacing the emergence of new strains.
The general technology whereby you can humanize a gene by transplanting large (>10 kb) pieces of genes via CRISPR is available and readily applicable thanks to CFCM facility in San Raffaele Hospital. Contact us or Lorenza Ronfani for more information.

HMGBiotech Srl can provide comprehensive information to facilitate your researches.
Discover more about our LPS free proteins for your in vitro and in vivo researches and contact us for your pre-sales questions.

Read the full article about the study:

Shopping Cart